A challenge You are passionate about providing an intervention (drug or device) to a group of patients who can’t access the current options due to availability or pricing. You could could go the philanthropic route to pay for the interventions. You could work towards regulation to apply downward pressure on pricing. No matter what, you have to
There were a few long reads that I’ll be re-reading over the weekend, including: New blood (at Fortune, by Roger Parloff @rparloff) This article profiles the blood diagnostics company, Theranos, and the founder, Elizabeth Holmes. While you will find the founder description interesting, I found myself drawn to the questions of business model, trade secrets and regulation.
Risk Distribution In WIRED, “One Startup’s Struggle to Survive the Silicon Valley Gold Rush” by Gideon Lewis-Kraus is a very long read for a magazine article but works to compare/contrast the social and economic lives of tech startup founders and employees at larger tech companies. Here’s a passage that stuck with me for hours after reading the
This tweet recently caught my eye. (I’m assuming pharma here is drug related, including biotech.) We’ve certainly heard about the R&D cutbacks in pharma and lean/backyard/virtual biotech companies need their work done somewhere. But 2/3 of pharma R&D is to be done by outside labs?! One reason I was caught off guard is my own
I’ve escaped the cube farm long enough to share a few thoughts from BIO-Europe Spring in Turin. Quality vs. Quantity Finding the sweet spot between busy and busy work at a partnering conference can be a challenge. The theoretical benefit to casting a wide net is that you are more likely to catch someone’s interest.
The biotech New Year is being ushered in next week at the 31st Annual JP Morgan Healthcare Conference. Last year I wrote about why San Francisco is a biotech vortex the first week in January so this year I collected a couple of good posts about how fellow biotech folks prepare for and recover from
What is Tech UX? I was recently at a local event for entrepreneurs (thanks Capital Entrepreneurs) and struck up a conversation with someone I didn’t know. His response to my standard intro question — “So, what do you do?” — was “I’m a UX guy”. Based on my “smile and nod” response, I was fortunate
How can scientists successfully transition from academia to industry? This question has come to mind repeatedly in a variety of settings over the last six months or so. In response to this question, I propose that the pharma/biotech* industry step in to fill the gap between teaching people science, which academia does very well, and